Literature DB >> 1493435

Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia.

D A Galton1.   

Abstract

Chronic myeloid leukaemia (CML) is a generic term that include five apparently distinct entities. The best known form, the classical Ph-positive subtype, accounts for about 90% of all cases of CML. The morphology of its presentation blood film is highly characteristic but is also seen in about half of the remaining 10% of cases, which are Ph-negative. This classical morphological subtype, whether Ph-positive or Ph-negative I describe as 'chronic granulocytic leukaemia' to refer to the exuberant granulocytic proliferation which is its hallmark. This term is often used indiscriminately and interchangeably with 'chronic myeloid leukaemia' and similar terms, just as 'chronic lymphocytic leukaemia' was, until recently, used to cover the chronic lymphoid leukaemias in general, but is now used in a specific sense. Chronic granulocytic leukaemia (CGL), whether Ph-positive or Ph-negative, is almost always BCR-rearranged and associated with the production of a unique 210-kd protein with enhanced tyrosine kinase activity. Most of the remaining cases of Ph-negative CML are examples of either chronic myelomonocytic leukaemia (CMML), a subtype almost as homogeneous as CGL, and characterized in its presentation blood film by the presence of monocytes and neutrophils but few immature granulocytes, or atypical CML (aCML), distinct from and less homogeneous than either CGL or CMML, in which some cases also share features with CGL while others share some with CMML. CMML and aCML do not show BCR rearrangement and are not associated with the production of p210kd. CGL, CMML, and aCML, though characterized on morphological features differ in their clinical features and behaviour, response to treatment and survival.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1493435     DOI: 10.3109/10428199209049789

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.

Authors:  Ivo P Touw; Renée Beekman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

2.  Is the practice of haematology evidence based? II. Evidence based morphological diagnosis.

Authors:  M M Reid; M J Galloway
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

3.  Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.

Authors:  Huifang Jiang; Zhonglin Wu; L I Ren; Diehong Tao; Hongyan Tong
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

4.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

Review 5.  Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.

Authors:  Stefania Rocca; Giovanna Carrà; Pietro Poggio; Alessandro Morotti; Mara Brancaccio
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

Review 6.  Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm.

Authors:  Joanna E Drozd-Sokołowska; Anna Waszczuk-Gajda; Krzysztof Mądry; Jadwiga Dwilewicz-Trojaczek
Journal:  Contemp Oncol (Pozn)       Date:  2018-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.